PODCAST: Discovering diseases with artificial intelligence. Listen to this episode of Binary Dreams – Cat!apult with COO Dr. Corinne Solier.
Continue readingPODCAST: Discovering diseases with artificial intelligence
Scailyte Closes Financing Round and Onboards Top Biotech Leaders
Scailyte has successfully finished the first closing of their series A. Two new investors joined the round, and most of the existing shareholders engaged with follow-on investments. The second closing is planned for the first half of 2022 and Scailyte is currently in discussions with a number of additional investors.
Continue readingScailyte Quarterly Update December 2021
December 2021 Quarterly update on Scailyte’s progress towards its mission to save millions of lives.
Continue readingVACANCY: Regulatory Affairs / Quality Management Specialist
We are currently developing a first-in-class in vitro diagnostic tool for Endometriosis aiming at cutting the time to diagnosis by years and improving the quality of life of millions of women. We look to strengthen our team with a Regulatory Affairs / Quality Management Specialist, passionate about making a change for patients, eager to learn and grow professionally, and dedicated to delivering top quality results.
Continue readingUsing single-cell data to deconstruct a human autoimmune disease
Watch Scailyte’s webinar on “Using single-cell data to deconstruct a human autoimmune disease” with Professor Dr Michael Brenner.
Continue readingWhy single-cell technologies are vital for Endometriosis research webinar
Watch Scailyte’s webinar on “Why single-cell technologies are vital for Endometriosis research” with Professor Dr Michael Mueller.
Continue readingSingle-Cell Discovery Grant in Oncology and Immunology
Open grant call of up to 100K Euro aimed at addressing unmet clinical needs in Oncology and Immunology.
Continue readingScailyte and Lexogen create a joint biomarker discovery workflow
Scailyte, a single-cell biomarker discovery company and Lexogen, a leader in RNA sequencing solutions, announce a strategic partnership. The companies will create a joint biomarker discovery workflow, leveraging Lexogen’s new single-cell RNA sequencing platform LUTHOR™ and Scailyte’s AI-driven analytics platform ScaiVision™.
Continue readingScailyte Quarterly Update June 2021
June 2021 Quarterly update on Scailyte’s progress towards its mission to save millions of lives.
Continue readingMichael Brenner, of Harvard Medical School, joins Scailyte as advisor
Artificial Intelligence (AI)-driven biomarker discovery innovator Scailyte announced today that Michael Brenner MD, Elizabeth Fay Brigham Professor of Medicine at Harvard Medical School, has joined Scailyte as an advisor to the Board of Directors.
Continue reading